Next steps unclear as Roche's inclacumab meets Phase II endpoint in post-angioplasty study
This article was originally published in Scrip
Executive Summary
Roche's inclacumab (RG1512) reduced heart tissue damage in patients with acute coronary syndromes who were dosed with the p-selectin antagonist prior to angioplasty in a Phase II clinical trial, but the Swiss drug maker has not indicated how or whether it will move forward with the monoclonal antibody licensed from Genmab.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.